NantHealth (NH) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of NantHealth (NASDAQ:NH) from a strong sell rating to a sell rating in a report published on Tuesday morning.

Several other research analysts have also recently weighed in on the company. Zacks Investment Research cut NantHealth from a buy rating to a hold rating in a research note on Wednesday, October 25th. Canaccord Genuity decreased their price target on NantHealth from $6.00 to $5.00 and set a buy rating for the company in a research note on Friday, November 17th. Finally, Jefferies Group restated a buy rating and issued a $5.00 price target on shares of NantHealth in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $8.05.

NantHealth (NASDAQ NH) traded up $0.01 during mid-day trading on Tuesday, hitting $3.77. The stock had a trading volume of 194,612 shares, compared to its average volume of 157,598. NantHealth has a 52-week low of $2.60 and a 52-week high of $10.19. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $407.32, a PE ratio of -2.12 and a beta of -1.50.

NantHealth (NASDAQ:NH) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The firm had revenue of $21.76 million during the quarter, compared to analysts’ expectations of $29.42 million. During the same quarter in the previous year, the business earned ($0.18) earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. analysts expect that NantHealth will post -1.35 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. purchased a new stake in NantHealth during the second quarter valued at $102,000. GSA Capital Partners LLP purchased a new stake in NantHealth during the second quarter valued at $121,000. Teachers Advisors LLC increased its position in NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after buying an additional 24,588 shares in the last quarter. California State Teachers Retirement System increased its position in NantHealth by 132.4% in the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new stake in NantHealth in the third quarter worth about $180,000. Institutional investors own 7.10% of the company’s stock.

WARNING: “NantHealth (NH) Stock Rating Upgraded by BidaskClub” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/13/nanthealth-nh-stock-rating-upgraded-by-bidaskclub.html.

NantHealth Company Profile

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit